Jmcll, that reading was not what was stated, and the distinction matters sufficiently enough to correct it precisely.
The claim was not that leronlimab cannot decrease tumor size directly. The claim was that leronlimab does not function as a standalone cytotoxic agent in the way a chemotherapy drug kills tumor cells by direct chemical interaction. Those are different statements, and the difference is important.
Here is what the published literature actually shows about how leronlimab decreases tumor burden, and why the sequence matters more than whether an ICI is present.
The Cancer Research peer-reviewed paper published in AACR journals documented specifically in colorectal cancer that CCL5/RANTES, the primary ligand for CCR5, recruits CCR5-bearing regulatory T cells into the tumor and enhances their ability to kill antitumor CD8+ T cells through TGF-β-mediated apoptosis. This is the suppressive mechanism operating in mCRC specifically: CCL5 arrives, CCR5-bearing Tregs move into position, those Tregs kill the CD8+ cytotoxic T cells that would otherwise attack the tumor, and the tumor grows without immune interference. Tumor growth was diminished in mice lacking CCR5, where a corresponding decrease in both Treg infiltration and CD8+ T cell apoptosis was noted.
When leronlimab blocks CCR5, that Treg recruitment mechanism stops. The CCL5 signal arrives at the receptor and finds the gate sealed. The Tregs that would have migrated into position to kill the CD8+ T cells cannot execute that migration. The CD8+ T cells that were being held in apoptosis by TGF-β-mediated Treg cytotoxicity survive and accumulate inside the tumor.
Now the key sequence: those CD8+ T cells, now present and functional inside the tumor because leronlimab removed the Treg-mediated killing mechanism, begin attacking tumor cells. The tumor responds to that immune pressure by upregulating PD-L1 as an adaptive defense. PD-L1 upregulation is not a starting condition. It is the tumor's response to being attacked by a functional immune system it was previously shielded from. This is exactly what the CCL5-deficiency CRC mouse model paper documented in PMC: CCL5 blockade in CRC facilitated CD8+ T cell accumulation into the tumor, and that immune pressure caused PD-L1 and PD-1 expression to upregulate as the tumor's downstream adaptive response.
The therapeutic window you identify is the period between when leronlimab removes the CCR5-mediated suppressive architecture, the Treg barrier collapses, the CD8+ T cells accumulate and begin killing tumor cells, and before the tumor has fully upregulated PD-L1 to impose the next layer of immune evasion. During that window, the CD8+ T cells are executing cytotoxic kills against tumor cells without the PD-1 brake being the dominant constraint. This is where the bulk of the tumor reduction happens through the immune mechanism, not through direct chemical toxicity from leronlimab itself, but through restored CD8+ T cell-mediated killing in a microenvironment from which the primary suppressive architecture has been removed.
If an ICI is present simultaneously, it releases the PD-1 brake on those same CD8+ T cells, extending and amplifying the killing window beyond the period before PD-L1 upregulates fully. If an ICI is not present, as in the CLOVER backbone using TAS-102 plus bevacizumab, the killing window during that pre-PD-L1-upregulation phase is the primary immune contribution, combined with the fourth activity layer of CCR5-dependent metabolic and cell cycle disruption sensitizing those tumor cells to TAS-102's DNA damage simultaneously.
On your second question about whether there is published data showing higher CCR5 receptor presence with lower levels of PD-L1: the CCL5-deficiency CRC paper answers this directly and in the opposite causal direction than most people expect.
In the CCL5-intact tumor, CCR5 is active, Tregs are killing CD8+ T cells, and PD-L1 is not being strongly upregulated because the immune system is not pressing hard enough against the tumor to trigger the adaptive PD-L1 response.
When CCL5 is blocked and CCR5 signaling stops, CD8+ T cells accumulate, immune pressure rises, and PD-L1 upregulates in response to that pressure.
So the published data supports: high CCR5 activity correlates with relatively lower PD-L1 upregulation, not because CCR5 suppresses PD-L1 directly, but because CCR5-mediated suppression prevents the immune pressure that would cause PD-L1 to rise. This is consistent with the CLOVER biopsy finding of PD-L1 CPS rising from one percent at baseline to five percent after leronlimab treatment: the drug removed the CCR5-mediated suppression, the CD8+ T cells pressed in, and the tumor responded by upregulating PD-L1 as its next adaptive move.
Leronlimab reduces tumor burden. The mechanism is immune architecture restoration followed by CD8+ T cell-mediated killing during the pre-PD-L1-upregulation window, with chemotherapy sensitization operating in parallel in the CLOVER backbone.
The sequence is the mechanism.
The claim was not that leronlimab cannot decrease tumor size directly. The claim was that leronlimab does not function as a standalone cytotoxic agent in the way a chemotherapy drug kills tumor cells by direct chemical interaction. Those are different statements, and the difference is important.
Here is what the published literature actually shows about how leronlimab decreases tumor burden, and why the sequence matters more than whether an ICI is present.
The Cancer Research peer-reviewed paper published in AACR journals documented specifically in colorectal cancer that CCL5/RANTES, the primary ligand for CCR5, recruits CCR5-bearing regulatory T cells into the tumor and enhances their ability to kill antitumor CD8+ T cells through TGF-β-mediated apoptosis. This is the suppressive mechanism operating in mCRC specifically: CCL5 arrives, CCR5-bearing Tregs move into position, those Tregs kill the CD8+ cytotoxic T cells that would otherwise attack the tumor, and the tumor grows without immune interference. Tumor growth was diminished in mice lacking CCR5, where a corresponding decrease in both Treg infiltration and CD8+ T cell apoptosis was noted.
When leronlimab blocks CCR5, that Treg recruitment mechanism stops. The CCL5 signal arrives at the receptor and finds the gate sealed. The Tregs that would have migrated into position to kill the CD8+ T cells cannot execute that migration. The CD8+ T cells that were being held in apoptosis by TGF-β-mediated Treg cytotoxicity survive and accumulate inside the tumor.
Now the key sequence: those CD8+ T cells, now present and functional inside the tumor because leronlimab removed the Treg-mediated killing mechanism, begin attacking tumor cells. The tumor responds to that immune pressure by upregulating PD-L1 as an adaptive defense. PD-L1 upregulation is not a starting condition. It is the tumor's response to being attacked by a functional immune system it was previously shielded from. This is exactly what the CCL5-deficiency CRC mouse model paper documented in PMC: CCL5 blockade in CRC facilitated CD8+ T cell accumulation into the tumor, and that immune pressure caused PD-L1 and PD-1 expression to upregulate as the tumor's downstream adaptive response.
The therapeutic window you identify is the period between when leronlimab removes the CCR5-mediated suppressive architecture, the Treg barrier collapses, the CD8+ T cells accumulate and begin killing tumor cells, and before the tumor has fully upregulated PD-L1 to impose the next layer of immune evasion. During that window, the CD8+ T cells are executing cytotoxic kills against tumor cells without the PD-1 brake being the dominant constraint. This is where the bulk of the tumor reduction happens through the immune mechanism, not through direct chemical toxicity from leronlimab itself, but through restored CD8+ T cell-mediated killing in a microenvironment from which the primary suppressive architecture has been removed.
If an ICI is present simultaneously, it releases the PD-1 brake on those same CD8+ T cells, extending and amplifying the killing window beyond the period before PD-L1 upregulates fully. If an ICI is not present, as in the CLOVER backbone using TAS-102 plus bevacizumab, the killing window during that pre-PD-L1-upregulation phase is the primary immune contribution, combined with the fourth activity layer of CCR5-dependent metabolic and cell cycle disruption sensitizing those tumor cells to TAS-102's DNA damage simultaneously.
On your second question about whether there is published data showing higher CCR5 receptor presence with lower levels of PD-L1: the CCL5-deficiency CRC paper answers this directly and in the opposite causal direction than most people expect.
In the CCL5-intact tumor, CCR5 is active, Tregs are killing CD8+ T cells, and PD-L1 is not being strongly upregulated because the immune system is not pressing hard enough against the tumor to trigger the adaptive PD-L1 response.
When CCL5 is blocked and CCR5 signaling stops, CD8+ T cells accumulate, immune pressure rises, and PD-L1 upregulates in response to that pressure.
So the published data supports: high CCR5 activity correlates with relatively lower PD-L1 upregulation, not because CCR5 suppresses PD-L1 directly, but because CCR5-mediated suppression prevents the immune pressure that would cause PD-L1 to rise. This is consistent with the CLOVER biopsy finding of PD-L1 CPS rising from one percent at baseline to five percent after leronlimab treatment: the drug removed the CCR5-mediated suppression, the CD8+ T cells pressed in, and the tumor responded by upregulating PD-L1 as its next adaptive move.
Leronlimab reduces tumor burden. The mechanism is immune architecture restoration followed by CD8+ T cell-mediated killing during the pre-PD-L1-upregulation window, with chemotherapy sensitization operating in parallel in the CLOVER backbone.
The sequence is the mechanism.
9
